ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial

Diarrhea Clinical Trial

Official title:

Treatment and Prevention of Oral and Alimentary Mucositis Using Polymerized Cross-Linked High Potency Sucralfate as a Single Agent Therapy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02016807
• Other study ID #: MMI-008
• Status: Active, not recruiting
• Phase: Phase 4
• First received: December 8, 2013
• Last updated: December 16, 2013
• Start date: January 2013
• Est. completion date: January 2015

Study information

• Verified date: December 2013
• Source: Ashley Downs Bioscience
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

RATIONALE: Polymerized (cross-linked) sucralfate malate paste (ProThelial) may be an effective single therapy approach for the management of chemoradiation mucositis, treating and preventing its occurrence in the oral cavity, esophagus, stomach, small and large intestine.

PURPOSE: This observational multi-phase trial is studying how well polymerized (cross-linked) sucralfate malate paste (ProThelial) works to prevent and treat mucositis in adult patients who are to receive or have received chemo/radiation therapy that have caused or is anticipated to cause mucositis in the oral cavity, esophagus, stomach, small or large intestine. The Phase IV study addresses prevention and treatment in the oral cavity. The Phase I study addresses prevention and treatment in the esophagus, stomach, small and large intestine.

Description:

OBJECTIVES:

Primary

• Observe the incidence of mucositis in patients receiving ProThelial prior to developing chemoradiation mucositis in the oral cavity, esophagus, stomach, small or large intestine.

• Observe the change from baseline in symptoms & signs of mucositis in chemoradiation patients on Prothelial who have developed mucositis in the oral cavity, esophagus, stomach, small or large intestine.

Secondary

• Patient-reported quality of relief by ProThelial (treatment portion) Using Pain Visual Analogue Scale (PVAS) Using Difficulty Swallowing Visual Analogue Scale (DSVAS)

• To evaluate the safety and tolerability of ProThelial (Phase I non-oral uses)

• To observe the adverse event profile of ProThelial using patient-reported Questionnaire

• To observe effect on pain assessed day 1, 2,4,7,14,21 by Pain VAS

• To observe effect on oral ulcerations assessed day 1, 2,4,7,14,21 by OMAS

• To observe effect on symptoms of esophageal mucositis assessed day1, 2,4,7,14, 21using Difficulty Swallowing Visual Analogue Scale

• To observe effect on symptoms of gastric and small intestine mucositis assessed day 1,2,4,7,14,21 using the Nausea Visual Analogue Scale & the NCI GI Toxicity Scale for Nausea, Vomiting

• To observe effect on symptoms of large intestine mucositis assessed day 1,2,4,7,14,21 by NCI GI Toxicity Scale for Colonic Diarrhea

Tertiary

• Functional status prior to and following use of ProThelial (ECOG/Karnofsky) in patients with mucositis

OUTLINE:

This is a multicenter observation study with 3 treatment cohorts and 3 prevention cohorts. Patients are stratified according to gender, age, treatment, cancer under treatment (type & stage), the presence, type, & severity of mucositis.

• Treatment (active mucositis): Patients are grouped in accordance to the type of mucositis experienced - oral/esophageal, gastric/small intestine & colonic.

• ▪ Arm 1 Patients with oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) (Phase I)

• ▪ Arm 2 Patients with gastric/small intestinal mucositis (delayed nausea vomiting as prominent symptom/sign). (Phase I)

• ▪ Arm 3 Patients with chemoradiation diarrhea as their prominent symptom/sign. (Phase I)

• Prevention (no mucositis): Patients are grouped in accordance to type of mucositis anticipated - oral/esophageal, gastric/small intestine and colonic.

• ▪ Arm 4 Patients anticipated to develop oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs). (Phase IV)

• ▪ Arm 5 Patients anticipated to develop gastric/small intestinal mucositis (delayed nausea vomiting as prominent symptom/sign) (Phase I)

• ▪ Arm 6 Patients anticipated to develop chemoradiation diarrhea as their prominent symptom/sign. (Phase I)

BACKGROUND ON INTERVENTION: PROTHELIAL™ Polymerized High Potency Sucralfate Malate Paste

STANDARD POTENCY VS HIGH POTENCY SUCRALFATE IN MANAGING MUCOSITIS

Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO (Multinational Association of Supportive Care in Cancer/ International Society of Oral Oncology) for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa. In August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.

RAPID HEALING BY STANDARD POTENCY SUCRALFATE AT HIGH DOSES

Early sucralfate investigations showed that undissolved (thus high dose concentration) sucralfate adherent to the human gastric mucosa caused rapid mucosal changes within 10-60 minutes. These changes included the release of mucus and bicarbonate as well as vacuolization and exfoliation of superficial enterocytes being replaced by newly regenerated cells. Laboratory animals given high doses of standard potency sucralfate (3-20 times the standard 14mg/kg dose) were observed to resist gastric injury, rapidly heal mucosal injuries and showed increased secretion of luminal prostaglandins, mucus and bicarbonate. These mucosal changes were shown to be linked to the local expression of growth factor receptors and the secretion of epidermal growth factor. Later research identified that sucralfate-mediated mucosal changes are growth factor dependent. Independently investigators have concluded that sucralfate accelerates growth-factor mediated mucosal healing, though the mechanism is unclear.

RAPID HEALING BY HIGH POTENCY SUCRALFATE GIVEN AT LOW DOSES

High potency sucralfate is the active ingredient of ProThelial. At standard 14mg/kg doses, high potency sucralfate causes a 7-23 fold hyper-concentration of sucralfate on mucosal lining. In a placebo controlled, double blinded multi-center trial involving 60 patients, there was a 28 day 87.7% healing rate of GERD erosions (compared to placebo's 37.7%) in patients using high potency sucralfate at 1.5 gram twice daily. This represented a 2.34 fold or 334% improvement in healing over placebo. Esophageal erosions in both treatment groups were exposed to untreated gastric acid making the results observed with high potency sucralfate that much more remarkable.

Similarly, in a randomized 7 day four-arm trial involving 41 patients with erosive GERD, the rate of healing for patients using high potency sucralfate was 80%. The 7 day healing rate for acid therapy groups were considerably lower: omeprazole (20mg bid) was 30% and for ranitidine (150mg bid) and antacid groups healing was 0%. Apparently the topical coating of high potency sucralfate affects a mucosa-centric mechanism for healing that appears indifferent to gastric pH or acid exposure. Comparing the 7 day healing rate of high potency sucralfate to that of omeprazole there was a 2.67 or 367% improvement similar to that seen when high potency sucralfate is compared to placebo where there was a 2.34 fold or 334% improvement.

EXPERIENCE USING HIGH POTENCY SUCRALFATE FOR ORAL & ALIMENTARY MUCOSITIS IN STAGE 4B HEAD AND NECK CANCER

In a 42 yo head and neck patient treated simultaneously with paclitaxel, carboplatin and radiation (201Gy), high potency sucralfate (HPS - ProThelial) prevented mucositis, allowing continuance of standard oral diet. The percutaneous gastric-tube surgically placed in anticipation of Grade 3-4 mucositis was never used by the patient. While on ProThelial, the patient never developed mucositis. Noncompliant discontinuation of HPS by patient midway through chemo-radiation led to the emergence oral and alimentary mucositis with oral erythema, nausea and diarrhea. Two days following resumption of HPS, both oral and alimentary mucositis disappeared. Throughout treatment with ProThelial a normal oral diet was maintained and no analgesia was required for mucositis. Patient reported no adverse events while on HPS for 6 weeks.

PROTHELIAL'S DEVICE MECHANISM OF ACTION - EXPEDITED HEALING

High potency sucralfate in polymerized sucralfate malate paste has a device mechanism of action. It is assumed that the more efficient layering of polymerized sucralfate paste produces adherent restrictive microenvironment across the mucosal lining which advantages the activation of growth factor receptors by growth factor. Restrictive micro-environs generated by cross-linked layers of polymerized sucralfate "crowds" free-moving growth factor, limiting its random movements to "pockets" that overlie growth factor receptors. Spatially limiting the movement of growth factor to the vicinity of its receptor heightens the chances of receptor site activation. This device action leads to expedited healing.

PROTHELIAL'S DEVICE MECHANISM OF ACTION - REVERSING MUCOSA-BASED PAIN, NAUSEA, VOMITING & DIARRHEA

The surface "pockets" of restrictive micro-environs created by Prothelial's unique layering probably affect the flux of ions across mucosal receptors responsible for pain, nausea, vomiting and neuro-secretory diarrhea. These specialized mucosal receptors triggered by chemo-radiation maintain their state of activation by means of gated-ion fluxes across surface membranes that face the lumen of the gut. It is probable that the same restrictive micro-environs that crowd growth factors to the vicinity of their receptors also affect the surrounding space available to membranes for ion-flux and exchange. Spatial limitation of the immediate surface environment surrounding ion-gated receptors along the GI tract impact the receptor's ability to perpetuate the ion fluxes required to keep the receptor "turned on" or stimulated. Physically restrictive micro-environs surrounding membranes of stimulated receptors exhaust the ions immediately available to it for exchange. This limits the ability of the receptor to stay "on". The result is the quiescence of the membrane and the reduction of receptor-associated pain, nausea (thereby vomiting) and neurosecretory diarrhea, all of which are triggered by chemoradiation therapy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 180
• Est. completion date: January 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 95 Years

Eligibility

Inclusion Criteria:

• 18 years and older

• Informed consent

• Patients receiving cancer therapy with agents likely to cause mucositis

• Patients who have developed mucositis from chemo/and or radiation

• Patients to receive these that cause nausea, vomiting

• Patients to receive these that cause diarrhea

• Patients with Head & Neck cancer to receive chemo/radiation and G-Tube

• Patients to undergo Hematopoietic Stem Cell Transplantation

Exclusion Criteria:

• Absence of consent

• Unable or unwilling to complete the self assessment questionnaire.

• Use of any mouthwash out of study

• Simultaneous treatment by an agent for prevention/treatment of mucositis

• Patients with baseline creatinine level greater than or equal to 3 or any patient with renal insufficiency requiring dialysis

• Have known allergies or intolerance to ProThelial or its ingredients (sucralfate)

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Diarrhea
• Mucositis
• Nausea
• Oral Mucositis
• Stomatitis
• Vomiting

Intervention

Device:
• ProThelial
August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.

Locations

Country	Name	City	State
United States	Translational Medicine Research Center	Foster	Rhode Island

Sponsors (1)

Lead Sponsor	Collaborator
Ashley Downs Bioscience

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Participants with Serious and Non-Serious Adverse Events	Safety/Adverse Event Outcome Measure	Up to 6 weeks	Yes
Other	Number of participants requiring the use of PEG (percutaneous endoscopic gastrostomy) tube feeding		Up to 6 weeks	No
Other	The milligrams of narcotic analgesic used daily by participants		Up to 6 weeks	No
Other	The milligrams of anti-emetic and anti-diarrheals used daily by participants		Up to 6 weeks	No
Primary	Change from Baseline in Oral Mucositis Assessment Score (OMAS) at Day 1, 2,4,7,14,21	Measures are to report the change from baseline in the OMAS used to assess patient in the prevention of oral mucositis by ProThelial (Phase IV)	Baseline, Day 1, 2, 4, 7, 14, 21	No
Primary	Change from Baseline in Oral Mucositis Assessment Score (OMAS) at Day 1, 2,4,7,14,21	Measures are to report the change from baseline in the OMAS used to assess patient in the treatment of oral mucositis by ProThelial (Phase IV)	Baseline, Day 1, 2,4,7,14,21	No
Secondary	Change from baseline in Pain as measured by Pain Visual Analogue Scale (PVAS) at Day1, 2,4,7,14, 21	PVAS is to be used to assess patient-reported pain of chemoradiation mucositis while under treatment with ProThelial (Phase IV)	Baseline, Day 1, 2, 4, 7,14,21	No
Secondary	Change from baseline in difficulty swallowing as measured by Difficulty Swallowing Visual Analogue Scale (DSVAS) at Day 1, 2,4,7,14,21	DSVAS will be used to assess difficulty in swallowing in patients with chemoradiation mucositis under treatment with ProThelial (Phase I)	Baseline, Day 1, 2,4,7,14, 21	Yes
Secondary	Change from baseline in toxicity grade of mucositis as measured by NCI Toxicity Grade for Alimentary Mucositis at Day 1, 2,4,7,14,21	NCI Toxicity Grading of Alimentary Mucositis will be used to assess the degree of nausea, vomiting and diarrhea caused by chemoradiation (Phase I).	Baseline, Day 1, 2,4,7,14,21	Yes